The Greater Cannabis Company, Inc. (GCAN) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 01, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	000-56027
Entity Registrant Name	THE GREATER CANNABIS COMPANY, INC.
Entity Central Index Key	0001695473
Entity Tax Identification Number	30-0842570
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	15 Walker Avenue Suite 101
Entity Address, City or Town	Baltimore
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21208
City Area Code	(443)
Local Phone Number	738-4051
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		804,638,436

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash	$ 62,282	$ 166,859
Total current assets	62,282	166,859
OTHER ASSETS
Right of first refusal agreement cost (less accumulated amortization of $23,333 and $19,583)	1,667	5,417
Total assets	63,949	172,276
CURRENT LIABILITIES
Accounts payable	6,418	6,094
Accrued interest	72,669	55,627
Accrued officers’ compensation	350,350	340,350
Notes payable to third parties	171,437	171,437
Total current liabilities and total liabilities	860,874	833,508
STOCKHOLDERS’ (DEFICIENCY)
Preferred stock; 19,000,000 shares authorized, $.001 par value: Series A Convertible Preferred-issued and outstanding 9,111,998 and 9,111,998 shares, respectively	9,112	9,112
Common stock; 2,000,000,000 shares authorized, $.001 par value, as of September 30, 2024 and December 31, 2023, there are 804,638,436 shares outstanding, respectively	804,639	804,639
Additional paid-in capital	3,006,321	3,006,321
Accumulated deficit	(4,616,997)	(4,481,304)
Total stockholders’ (deficiency)	(796,925)	(661,232)
Total liabilities and stockholders’ (deficiency)	63,949	172,276
Related Party [Member]
CURRENT LIABILITIES
Loans payable to related parties	$ 260,000	$ 260,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accumulated amortization	$ 23,333	$ 19,583
Preferred stock, shares authorized	19,000,000	19,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares outstanding	804,638,436	804,638,436
Series A Convertible Preferred Stock [Member]
Preferred stock, shares issued	9,111,998	9,111,998
Preferred stock, shares outstanding	9,111,998	9,111,998

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Total revenue
512Cost of product sales
Gross profit (loss)
Operating Expenses:
Officers compensation	30,000	30,000	90,000	90,000
Amortization of Right of First Refusal Agreement cost	1,250	1,250	3,750	3,750
Other operating expenses	9,193	19,215	24,901	37,587
Total operating expenses	40,443	50,465	118,651	131,337
Income (loss) from operations	(40,443)	(50,465)	(118,651)	(131,337)
Other income (expenses):
Interest expense	(5,722)	(2,965)	(17,042)	(10,204)
Loss on conversions/issuances of notes payable
Total other income (expenses)	(5,722)	(2,965)	(17,042)	(10,204)
Income (loss) before provision for income taxes	(46,165)	(53,430)	(135,693)	(141,541)
Provision for income taxes
Net loss	$ (46,165)	$ (53,430)	$ (135,693)	$ (141,541)
Basic income (loss) per common share	$ 0	$ 0	$ 0	$ 0
Diluted income (loss) per common share	$ 0	$ 0	$ 0	$ 0
Weighted average common shares outstanding-basic	804,638,436	766,682,836	804,638,436	743,973,236
Weighted average common shares outstanding-diluted	804,638,436	766,682,836	804,638,436	743,973,236
Product [Member]
Revenue:
Total revenue
Consulting Fees [Member]
Revenue:
Total revenue

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Balances	$ (750,760)	$ (705,843)	$ (661,232)	$ (632,941)	$ (587,898)	$ (544,830)	$ (661,232)	$ (544,830)
Net loss	(46,165)	(44,917)	(44,611)	(53,430)	(45,043)	(43,068)	(135,693)	(141,541)
Conversion of note payable ($36,000) and accrued interest ($0) into 36,000,000 shares of common stock (Fair Value $36,000)				36,000
Balances	(796,925)	(750,760)	(705,843)	(650,371)	(632,941)	(587,898)	(796,925)	(650,371)
Preferred Stock [Member] | Series A Preferred Stock [Member]
Balances	$ 9,112	$ 9,112	$ 9,112	$ 9,112	$ 9,112	$ 9,112	$ 9,112	$ 9,112
Balance, shares	9,111,998	9,111,998	9,111,998	9,411,998	9,111,998	9,111,998	9,111,998	9,111,998
Net loss
Conversion of note payable ($36,000) and accrued interest ($0) into 36,000,000 shares of common stock (Fair Value $36,000)
Balances	$ 9,112	$ 9,112	$ 9,112	$ 9,112	$ 9,112	$ 9,112	$ 9,112	$ 9,112
Balance, shares	9,111,998	9,111,998	9,111,998	9,111,998	9,411,998	9,111,998	9,111,998	9,111,998
Common Stock [Member]
Balances	$ 804,639	$ 804,639	$ 804,639	$ 732,639	$ 732,639	$ 732,639	$ 804,639	$ 732,639
Balance, shares	804,638.436	804,638,436	804,638,436	732,638,436	732,638,436	732,638,436	804,638,436	732,638,436
Net loss
Conversion of note payable ($36,000) and accrued interest ($0) into 36,000,000 shares of common stock (Fair Value $36,000)				$ 36,000
Conversion of note payable and accrued interest into shares of common stock, shares				36,000,000
Balances	$ 804,639	$ 804,639	$ 804,639	$ 768,639	$ 732,639	$ 732,639	$ 804,639	$ 768,639
Balance, shares	804,638.436	804,638.436	804,638,436	768,638,436	732,638,436	732,638,436	804,638.436	768,638,436
Additional Paid-in Capital [Member]
Balances	$ 3,006,321	$ 3,006,321	$ 3,006,321	$ 3,006,321	$ 3,006,321	$ 3,006,321	$ 3,006,321	$ 3,006,321
Net loss
Balances	3,006,321	3,006,321	3,006,321	3,006,321	3,006,321	3,006,321	3,006,321	3,006,321
Retained Earnings [Member]
Balances	(4,570,832)	(4,525,915)	(4,481,304)	(4,381,013)	(4,335,970)	(4,292,902)	(4,481,304)	(4,292,902)
Net loss	(46,165)	(44,917)	(44,611)	(53,430)	(45,043)	(43,068)
Balances	$ (4,616,997)	$ (4,570,832)	$ (4,525,915)	$ (4,434,443)	$ (4,381,013)	$ (4,335,970)	$ (4,616,997)	$ (4,434,443)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficiency (Unaudited) (Parenthetical) - USD ($)				3 Months Ended
	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Sep. 30, 2023	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Statement of Financial Position [Abstract]
Notes payable				$ 36,000
Interest payable	$ 515	$ 4,015	$ 2,680	$ 0
Shares of common stock	637,273	1,468,204	1,748,363	36,000,000	261,215,948	115,277,834	27,563,525	21,484,688
Fair value of common stock				$ 36,000	$ 804,324	$ 797,067	$ 210,532	$ 406,093

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
OPERATING ACTIVITIES
Net (loss)	$ (135,693)	$ (141,541)
Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:
Amortization of Right of First Refusal Agreement cost	3,750	3,750
Changes in operating assets and liabilities:
Accounts payable	324	(12,911)
Accrued interest	17,042	10,204
Accrued officers’ compensation	10,000	70,000
Net cash used in operating activities	(104,577)	(70,498)
INVESTING ACTIVITIES
Net cash used in investing activities
FINANCING ACTIVITIES
Net cash provided by financing activities
NET (DECREASE) IN CASH	(104,577)	(70,498)
CASH BALANCE, BEGINNING OF PERIOD	166,859	270,030
Interest paid
Income tax paid
Non-cash Investing and Financing Activities:
Conversion of note payable ($36,000) and accrued interest ($0) into 36,000,000 shares of common stock (Fair Value of $36,000) for the three months ended September 30, 2023		$ 36,000

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)				3 Months Ended
	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Sep. 30, 2023	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Statement of Cash Flows [Abstract]
Notes payable				$ 36,000
Interest payable	$ 515	$ 4,015	$ 2,680	$ 0
Shares of common stock	637,273	1,468,204	1,748,363	36,000,000	261,215,948	115,277,834	27,563,525	21,484,688
Fair value of common stock				$ 36,000	$ 804,324	$ 797,067	$ 210,532	$ 406,093

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100 9,411,998 Each share of Series A Convertible Preferred Stock is convertible into 50 94 Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). After the consummation of the above-described transactions, the Company switched its business model in fiscal 2018 and no longer intended to pursue E-commerce, advertising, licensing (except as specified below) or direct investment operations. Instead, the Company is now engaged in the development and commercialization of innovative cannabinoid therapeutics. From July 2018 through mid-2021, the Company focused on commercializing its own and licensed technologies worldwide for transmucosal and transdermal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids. The Company’s initial product was an oral transmucosal patch platform which for provides for loaded actives to be absorbed by the buccal mucosa into the body. Although the Company was able to launch the product and received some limited initial orders, the Company’s management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability. Accordingly, on October 19, 2021 the Company entered into a license agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The license agreement covers the license of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. Accompanying the license agreement is a joint research and development agreement, which will focus on continuing the clinical program spearheaded by Dr. Adi Aran, M.D. Director of Pediatric Neurology at SZMC, Board Member of the Israeli Society for Pediatric Neurology, and co-inventor of the novel cannabinoid therapy. Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiary Biocanrx, Inc. All intercompany balances and transactions have been eliminated in consolidation. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Interim Financial Statements The interim financial statements as of June 30, 2024 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the nine months ended September 30, 2024 are not necessarily indicative of results that may be expected for the year ending December 31, 2024. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2023 as included in our report on Form 10-K. Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no in cash equivalents. Notes and Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses from the failure of its customers to make required payments for products and other consideration delivered. The Company estimates this allowance based on the age of the related receivable, knowledge of the financial condition of customers, review of historical receivables and reserve trends and other pertinent information. If the financial condition of customers deteriorates or an unfavorable trend in receivable collections is experienced in the future, additional allowances may be required. Historically, the Company’s reserves have approximated actual experience. Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of September 30, 2024, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods. Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values. Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Revenue Recognition Revenue recognition: The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on January 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, in accordance with the following five-step process: ● Identify the contract(s) with a customer ● Identify the performance obligations ● Determine the transaction price ● Allocate the transaction price ● Recognize revenue when the performance obligations are met During the periods presented, all revenue was from sales of cannabis products. The Company has determined the sole performance obligation to be the delivery of the purchased goods to the customers, and as such, recognizes revenue at the time the customer takes possession. Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs. Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 see NOTE E - NOTES PAYABLE TO THIRD PARTIES see NOTE G - CAPITAL STOCK AND WARRANTS THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Recently Enacted Accounting Standards In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on July 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently evaluating the impact of the adoption of ASU 2020-06 on our financial statements. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). Financial Instruments—Credit Losses (Topic 326) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. ASU 2016-13 affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this ASU will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our financial statements. Other standards not presented are not deemed to be material. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited)

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE B - GOING CONCERN Under ASC 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future obligations as they become due within one year after the date the financial statements are issued. As required by this standard, our evaluation shall initially not take into consideration the potential mitigating effects of our plans that have not been fully implemented as of the date the financial statements are issued. In performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to meet our financial obligations as they become due. As of September 30, 2024, the Company had cash of $ 62,282 860,874 798,592 135,693 104,577 In performing the second step of this assessment, we are required to evaluate whether our plans to mitigate the conditions above alleviate the substantial doubt about our ability to meet our obligations as they become due within one year after the date that the financial statements are issued. Our future plans include securing additional funding sources. There is no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available through external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material effect on the business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing shareholders. We have therefore concluded there is substantial doubt about our ability to continue as a going concern through September 2025. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty related to our ability to continue as a going concern. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited)

RIGHT OF FIRST REFUSAL AGREEMEN

RIGHT OF FIRST REFUSAL AGREEMENT	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
RIGHT OF FIRST REFUSAL AGREEMENT	NOTE C – RIGHT OF FIRST REFUSAL AGREEMENT On January 30, 2020, the Company executed a Right of First Refusal Agreement with an entity engaged in the business of cosmetics, health, and well-being. The Agreement provided for the Company to pay Kol Tuv Ventures, LLC (“KTV”), $ 25,000 five years 25,000

LOANS PAYABLE TO RELATED PARTIE

LOANS PAYABLE TO RELATED PARTIES	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
LOANS PAYABLE TO RELATED PARTIES	NOTE D - LOANS PAYABLE TO RELATED PARTIES Loans payable to related parties consist of: SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES September 30, December 31, Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 80,000 80,000 Total $ 260,000 $ 260,000 Pursuant to loan and contribution agreements dated July 31, 2018, the above loans are non-interest bearing and are to be repaid after the Company raises from investors no less than $ 1,500,000 THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited)

NOTES PAYABLE TO THIRD PARTIES

NOTES PAYABLE TO THIRD PARTIES	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
NOTES PAYABLE TO THIRD PARTIES	NOTE E - NOTES PAYABLE TO THIRD PARTIES Notes payable to third parties consist of: SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES September 30, 2024 December 31, 2023 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4 September 28, 2017 .001 $ 375 $ 375 Convertible Promissory Note dated March 15, 2021 payable to FirstFire Global Opportunities Fund, LLC (“FF”), interest at 6 March 11, 2022 0 0 (i) 171,062 171,062 Total $ 171,437 $ 171,437 (i) On March 15, 2021, we issued a 6 545,000 272,500 22,500 272,500 22,500 March 11, 2022 On June 1, 2022, the Company issued 25,000,000 25,000 .001 During the three months ended September 30, 2022, the Company issued 135,000,000 135,000 .001 During the three months ended December 31, 2022, the Company issued 64,000,000 64,000 .001 The FF Note may be pre-paid in whole or in part by paying FF the following premiums: SCHEDULE OF PREPAY AMOUNT AND DATE DESCRIPTION PREPAY DATE PREPAY AMOUNT ≤ 30 days 105% * (Principal + Interest (“P+I”) 31- 60 days 110% * (P+I) 61-90 days 115% * (P+I) 91-120 days 120% * (P+I) 121-150 days 125% * (P+I) 151-180 days 130% * (P+I) THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) Any amount of principal or interest on the FF Note, which is not paid when due shall bear interest at the rate of twenty-four ( 24 the date the Registration Statement (as defined below) covering the shares issuable upon conversion of the FFG Notes is declared effective by the Securities and Exchange Commission (the “SEC”) or (ii) one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the FF Note into fully paid and non-assessable shares of our common stock at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 7 0 In the case of an Event of Default (as defined in the Note), the FF Note shall become immediately due and payable in an amount (the “Default Amount”) equal to the principal amount then outstanding plus accrued interest (including any Default Interest) through the date of full repayment multiplied by one hundred twenty-five percent 125 Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021. The valuation of the above warrants issued and recorded during the three months ended June 30, 2021 was $ 262,429 See NOTE -G WARRANTS

DERIVATIVE LIABILITY

DERIVATIVE LIABILITY	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITY	NOTE F - DERIVATIVE LIABILITY The derivative liability consists of: SCHEDULE OF DERIVATIVE LIABILITY September 30, 2024 December 31, 2023 Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note E (i) March 11, 2022 $ - $ - Total derivative liability $ - $ - (i) As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019. The Convertible Promissory Notes (the “Notes”) contain a variable conversion feature based on the future trading price of the Company’s common stock. Therefore, the number of shares of common stock issuable upon conversion of the Notes is indeterminate. The fair value of the derivative liability is measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculation of the derivative liability of the Notes at December 31, 2020 were (1) stock price of $ .003 .00169 0 142.94 0 .0011 .0071 345 142.94 .07 (i)As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited)

CAPITAL STOCK AND WARRANTS

CAPITAL STOCK AND WARRANTS	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
CAPITAL STOCK AND WARRANTS	NOTE G - CAPITAL STOCK AND WARRANTS Preferred Stock On July 31, 2018, The Greater Cannabis Company, Inc. (the “Company”) acquired 100 9,411,998 Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock. On February 14, 2019, the Company issued 9,000,000 Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $ 0.075 On September 21, 2021, 300,000 15,000,000 Common Stock Effective March 10, 2017, in connection with a partial spin-off of the Company from Sylios Corp, the Company issued a total of 26,905,969 5,378,476 19.99 21,527,493 500 80.01 On January 4, 2019, the Company issued 769,785 670 100 0.001 99,302 100,072 769,785 770 On January 4, 2019, the Company issued 695,129 1,400 440,000 0.001 On April 16, 2019, the Company issued 1,384,600 40,500 7,961 131,537 179,998 1,384,600 47,961 On May 29, 2019, the Company issued a total of 542,000 75,880 542,000 THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) On August 15, 2019, the Company issued 175,000 12,250 175,000 On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $ 20,399 5,189 25,587 6 February 12, 2020 75 15 9,000,000 675,000 2 October 18, 2020 75 15 On November 11, 2019, the Company issued 1,748,363 53,705 2,680 On December 20, 2019, the Company issued 1,468,204 29,000 4,015 On December 24, 2019, the Company issued 637,273 10,000 515 During the three months ended March 31, 2020, the Company issued a total of 21,484,688 165,350 11,793 228,949 406,093 21,484,688 177,143 During the three months ended June 30, 2020, the Company issued a total of 27,563,525 67,082 10,613 132,838 210,532 27,563,525 77,695 During the three months ended September 30, 2020, the Company issued a total of 115,277,834 311,050 18,462 467,554 797,067 115,277,834 329,512 During the three months ended December 31, 2020, the Company issued a total of 261,215,948 325,212 16,849 462,263 804,324 261,215,948 342,061 During the three months ended March 31, 2021, the Company recorded the conversion of note payable ($ 22,500 814 13,795,118 45,525 During the three months ended June 30, 2021, the Company recorded the value of the warrants at $ 262,429 39,000 On July 15, 2021, the Company issued 10,000,000 52,080 .005208 During the year ended December 31, 2023, the Company issued 72,000,000 72,000 .001 THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) Warrants On March 11, 2021, in connection with the issuance of a Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”) (see Note F), we issued three warrants (Warrant A, Warrant B and Warrant C) to purchase shares of our common stock, as follows: Warrant A permits FF to purchase 25,000,000 0.025 Warrant B permits FF to purchase 15,000,000 0.05 Warrant C permits FF to purchase 10,000,000 0.075 Each warrant has other customary terms found in like instruments, including, but not limited to, events of default. In any event of default, the exercise price for each warrant automatically becomes $ 0.005 Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021 and the above summary of the warrant terms are subject to full terms of the applicable warrants. The valuation of the above warrants issued and recorded during the three months ended June 30, 2021 was $ 262,429

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE H - INCOME TAXES The Company and its United States subsidiaries file consolidated Federal income tax returns. Green C Corporation, its Ontario Canada subsidiary, files Canada and Ontario income tax returns. At September 30, 2024 the Company has available for federal income tax purposes a net operating loss carry forward that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company, it is not more likely than not that the benefits will be realized. If there are significant changes in the Company’s ownership, the future use of its existing net operating losses will be limited. All tax years of the Company and its United States subsidiaries remain subject to examination by the Internal Revenue Service. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited)

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE I - COMMITMENTS AND CONTINGENCIES Pharmedica Exclusive License Agreement On June 21, 2018, Green C executed an Exclusive License Agreement with Pharmedica, Ltd. (“Pharmedica”), an Israeli company, to exploit certain Pharmedica intellectual property for the development and distribution of a certain Licensed Product involved in the transmucosal delivery of medicinal or recreational cannabis. The agreement provides for Green C payments to Pharmedica of a $ 100,000 5 50,000 The Company generated only minimal revenues from this asset through December 31, 2019 and did not pay the Year 1 Minimum Annual Royalty of $ 50,000 69,749 69,749 0 On September 2, 2020, Green C notified Pharmedica of Green C’s termination of the Exclusive License Agreement and Green C’s intention to wind up Green C. On September 17, 2020, Pharmedica notified Green C of Pharmedica’s acceptance of Green C’s proposal to terminate the license agreement and Pharmedica’s intention not to burden Green C further. Accordingly, we recorded “Forgiveness of Royalty Payable” other income of $ 50,000 50,000 0 Sub-License Agreement with Symtomax Unipessoal Lda On July 15, 2019, the Company executed a Sub-License Agreement with Symtomax Unipessoal Lda (“Symtomax”). The agreement provides for the Company’s grant to Symtomax of a non-exclusive right and sub-license to use certain Company technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa. The agreement provides for Symtomax payments of royalties to the Company (payable monthly) ranging from 10 17 On May 27, 2020, the Company executed an amended and restated sub-license agreement with Symtomax (the “Amended License Agreement”). The term of the Amended License Agreement ends the earlier of (i) August 31, 2021 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $ 1,000,000 To date, Symtomax has not made any sales requiring the payment of royalties to the Company. Agreements On July 31, 2018, the Company executed Services Agreements with its newly appointed Chief Executive Officer (the “CEO”), for terms of five years. The Agreement provides for a monthly base salary of $ 10,000 90,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE J – SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date the financial statements were available to be issued. The Company had no subsequent events that require disclosure.

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100 9,411,998 Each share of Series A Convertible Preferred Stock is convertible into 50 94 Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). After the consummation of the above-described transactions, the Company switched its business model in fiscal 2018 and no longer intended to pursue E-commerce, advertising, licensing (except as specified below) or direct investment operations. Instead, the Company is now engaged in the development and commercialization of innovative cannabinoid therapeutics. From July 2018 through mid-2021, the Company focused on commercializing its own and licensed technologies worldwide for transmucosal and transdermal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids. The Company’s initial product was an oral transmucosal patch platform which for provides for loaded actives to be absorbed by the buccal mucosa into the body. Although the Company was able to launch the product and received some limited initial orders, the Company’s management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability. Accordingly, on October 19, 2021 the Company entered into a license agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The license agreement covers the license of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. Accompanying the license agreement is a joint research and development agreement, which will focus on continuing the clinical program spearheaded by Dr. Adi Aran, M.D. Director of Pediatric Neurology at SZMC, Board Member of the Israeli Society for Pediatric Neurology, and co-inventor of the novel cannabinoid therapy.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiary Biocanrx, Inc. All intercompany balances and transactions have been eliminated in consolidation. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Interim Financial Statements	Interim Financial Statements The interim financial statements as of June 30, 2024 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the nine months ended September 30, 2024 are not necessarily indicative of results that may be expected for the year ending December 31, 2024. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2023 as included in our report on Form 10-K.
Cash and Cash Equivalents	Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no in cash equivalents.
Notes and Accounts Receivable	Notes and Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses from the failure of its customers to make required payments for products and other consideration delivered. The Company estimates this allowance based on the age of the related receivable, knowledge of the financial condition of customers, review of historical receivables and reserve trends and other pertinent information. If the financial condition of customers deteriorates or an unfavorable trend in receivable collections is experienced in the future, additional allowances may be required. Historically, the Company’s reserves have approximated actual experience.
Income Taxes	Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of September 30, 2024, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Financial Instruments and Fair Value of Financial Instruments	Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods.
Derivative Liabilities	Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.
Long-lived Assets	Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services	Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values.
Related Parties	Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Revenue Recognition	Revenue Recognition Revenue recognition: The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on January 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, in accordance with the following five-step process: ● Identify the contract(s) with a customer ● Identify the performance obligations ● Determine the transaction price ● Allocate the transaction price ● Recognize revenue when the performance obligations are met During the periods presented, all revenue was from sales of cannabis products. The Company has determined the sole performance obligation to be the delivery of the purchased goods to the customers, and as such, recognizes revenue at the time the customer takes possession.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs.
Loss per Share	Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 see NOTE E - NOTES PAYABLE TO THIRD PARTIES see NOTE G - CAPITAL STOCK AND WARRANTS THE GREATER CANNABIS COMPANY, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the Nine Months Ended September 30, 2024 and 2023 (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Recently Enacted Accounting Standards	Recently Enacted Accounting Standards In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on July 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently evaluating the impact of the adoption of ASU 2020-06 on our financial statements. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). Financial Instruments—Credit Losses (Topic 326) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. ASU 2016-13 affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this ASU will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of the adoption of ASU 2016-13 on our financial statements. Other standards not presented are not deemed to be material.

LOANS PAYABLE TO RELATED PART_2

LOANS PAYABLE TO RELATED PARTIES (Tables)	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES	Loans payable to related parties consist of: SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES September 30, December 31, Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 80,000 80,000 Total $ 260,000 $ 260,000

NOTES PAYABLE TO THIRD PARTIES

NOTES PAYABLE TO THIRD PARTIES (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES	Notes payable to third parties consist of: SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES September 30, 2024 December 31, 2023 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4 September 28, 2017 .001 $ 375 $ 375 Convertible Promissory Note dated March 15, 2021 payable to FirstFire Global Opportunities Fund, LLC (“FF”), interest at 6 March 11, 2022 0 0 (i) 171,062 171,062 Total $ 171,437 $ 171,437 (i) On March 15, 2021, we issued a 6 545,000 272,500 22,500 272,500 22,500 March 11, 2022
SCHEDULE OF PREPAY AMOUNT AND DATE DESCRIPTION	The FF Note may be pre-paid in whole or in part by paying FF the following premiums: SCHEDULE OF PREPAY AMOUNT AND DATE DESCRIPTION PREPAY DATE PREPAY AMOUNT ≤ 30 days 105% * (Principal + Interest (“P+I”) 31- 60 days 110% * (P+I) 61-90 days 115% * (P+I) 91-120 days 120% * (P+I) 121-150 days 125% * (P+I) 151-180 days 130% * (P+I)

DERIVATIVE LIABILITY (Tables)

DERIVATIVE LIABILITY (Tables)	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF DERIVATIVE LIABILITY	The derivative liability consists of: SCHEDULE OF DERIVATIVE LIABILITY September 30, 2024 December 31, 2023 Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note E (i) March 11, 2022 $ - $ - Total derivative liability $ - $ - (i) As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares				9 Months Ended
	Jul. 31, 2018	Jul. 13, 2018	Mar. 10, 2017	Sep. 30, 2024
Number of shares issued			26,905,969
Series A Convertible Preferred Stock [Member]
Anti-dilutive shares excluded from computation				470,599,900
Green C Corporation [Member] | Former Share Holders [Member]
Percentage of issued and outstanding shares acquired	94%
Green C Corporation [Member] | Class A Common Stock [Member]
Percentage of issued and outstanding shares acquired	100%
Green C Corporation [Member] | Series A Convertible Preferred Stock [Member]
Number of shares issued	9,411,998	9,411,998
Common stock, voting rights	Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.
Conversion of convertible preferred stock	50

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 62,282						$ 62,282		$ 166,859
Liabilities, current	860,874						860,874
Working capital deficit	798,592						798,592
Net loss	$ 46,165	$ 44,917	$ 44,611	$ 53,430	$ 45,043	$ 43,068	135,693	$ 141,541
Cash used from operating activities							$ 104,577	$ 70,498

RIGHT OF FIRST REFUSAL AGREEM_2

RIGHT OF FIRST REFUSAL AGREEMENT (Details Narrative) - Kol Tuv Ventures, LLC [Member] - Right of First Refusal Agreement [Member] - CBD [Member]	Jan. 30, 2020 USD ($)
Product Liability Contingency [Line Items]
Payment for other invetsment opportunities	$ 25,000
Opportunities term	5 years
Amortization cost	$ 25,000

SCHEDULE OF LOANS PAYABLE TO RE

SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Total	$ 260,000	$ 260,000
Elisha Kalfa and Yonah Kalfa [Member]
Related Party Transaction [Line Items]
Total	180,000	180,000
Fernando Bisker and Sigalush LLC [Member]
Related Party Transaction [Line Items]
Total	$ 80,000	$ 80,000

SCHEDULE OF LOANS PAYABLE TO _2

SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) (Parenthetical) - Series A Convertible Preferred Stock [Member] - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Elisha Kalfa and Yonah Kalfa [Member]
Related Party Transaction [Line Items]
Total number of shares convertible	2,966,666	2,966,666
Fernando Bisker and Sigalush LLC [Member]
Related Party Transaction [Line Items]
Total number of shares convertible	2,966,666	2,966,666

LOANS PAYABLE TO RELATED PART_3

LOANS PAYABLE TO RELATED PARTIES (Details Narrative)	Jul. 31, 2018 USD ($)
Maximum [Member] | Loan and Contribution Agreements [Member]
Repayments of related party debt	$ 1,500,000

SCHEDULE OF NOTES PAYABLE TO TH

SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) - USD ($)		Sep. 30, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Total		$ 171,437	$ 171,437
Promissory Note [Member]
Short-Term Debt [Line Items]
Total		375	375
Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Total	[1]	$ 171,062	$ 171,062
[1]On March 15, 2021, we issued a 6 545,000 272,500 22,500 272,500 22,500 March 11, 2022

SCHEDULE OF NOTES PAYABLE TO _2

SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) (Parenthetical) - USD ($)	Jun. 30, 2021	Mar. 15, 2021	Mar. 28, 2017	Sep. 30, 2024	Dec. 31, 2023	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019
Short-Term Debt [Line Items]
Debt instrument, interest rate				24%
Debt instrument, principal amount						$ 10,000	$ 29,000	$ 53,705
Promissory Note [Member] | John T. Root [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate			4%
Debt instrument, maturity date			Sep. 28, 2017
Conversion price			$ 0.001
Convertible Promissory Note [Member] | FirstFire Global Opportunities Fund, LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate		6%
Debt instrument, maturity date	Mar. 11, 2022	Mar. 11, 2022
Unamortized discount				$ 0	$ 0
Debt instrument, principal amount		$ 545,000
Proceeds from issuance of convertible debt		272,500
Debt conversion, original issue discount		$ 22,500
Convertible Promissory Note [Member] | FirstFire Global Opportunities Fund, LLC [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Short-Term Debt [Line Items]
Proceeds from issuance of convertible debt	$ 272,500
Debt conversion, original issue discount	$ 22,500

SCHEDULE OF PREPAY AMOUNT AND D

SCHEDULE OF PREPAY AMOUNT AND DATE DESCRIPTION (Details) - FirstFire Note [Member]	9 Months Ended
	Sep. 30, 2024
Less than or Equal to 30 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	105% * (Principal + Interest (“P+I”)
31 - 60 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	110% * (P+I)
61 - 90 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	115% * (P+I)
91 - 120 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	120% * (P+I)
121 - 150 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	125% * (P+I)
151 - 180 Days [Member]
Short-Term Debt [Line Items]
Debt prepay amount, description	130% * (P+I)

NOTES PAYABLE TO THIRD PARTIE_2

NOTES PAYABLE TO THIRD PARTIES (Details Narrative) - USD ($)						3 Months Ended								9 Months Ended	12 Months Ended
	Jun. 01, 2022	Jul. 15, 2021	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Shares issued for conversion			637,273	1,468,204	1,748,363	36,000,000				261,215,948	115,277,834	27,563,525	21,484,688
Principal amount						$ 36,000				$ 804,324	$ 797,067	$ 210,532	$ 406,093
Debt Instrument, Interest Rate, Stated Percentage														24%
Long term debt description														the date the Registration Statement (as defined below) covering the shares issuable upon conversion of the FFG Notes is declared effective by the Securities and Exchange Commission (the “SEC”) or (ii) one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the FF Note into fully paid and non-assessable shares of our common stock at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 70% of the average closing price of our common stock for the five prior trading days prior to the date that a registration statement in respect of the shares into which is the FF Note is convertible is declared effective.
Debt default, description of event of default														In the case of an Event of Default (as defined in the Note), the FF Note shall become immediately due and payable in an amount (the “Default Amount”) equal to the principal amount then outstanding plus accrued interest (including any Default Interest) through the date of full repayment multiplied by one hundred twenty-five percent
Debt repayment percentage														125%
FirstFire Note [Member]
Short-Term Debt [Line Items]
Shares issued for conversion	25,000,000	10,000,000					64,000,000	135,000,000							72,000,000
Principal amount	$ 25,000						$ 64,000	$ 135,000
Conversion price	$ 0.001	$ 0.005208					$ 0.001	$ 0.001							$ 0.001
Second FirstFire Note [Member]
Short-Term Debt [Line Items]
Issuance of warrants									$ 262,429

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITY (Details) - USD ($)		Sep. 30, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Total derivative liability
Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Total derivative liability	[1]
[1]As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019.

SCHEDULE OF DERIVATIVE LIABIL_2

SCHEDULE OF DERIVATIVE LIABILITY (Details) (Parenthetical)	Jun. 30, 2021	Mar. 15, 2021
Convertible Promissory Note [Member] | FirstFire Global Opportunities Fund, LLC [Member]
Short-Term Debt [Line Items]
Debt Instrument, Maturity Date	Mar. 11, 2022	Mar. 11, 2022

DERIVATIVE LIABILITY (Details N

DERIVATIVE LIABILITY (Details Narrative) - Convertible Promissory Note [Member]	Mar. 31, 2021 $ / shares	Dec. 31, 2020 $ / shares
Measurement Input, Share Price [Member]
Short-Term Debt [Line Items]
Derivative liability measurement input	0.0011	0.003
Measurement Input, Conversion Price [Member]
Short-Term Debt [Line Items]
Derivative liability measurement input	0.0071	0.00169
Measurement Input, Expected Term [Member]
Short-Term Debt [Line Items]
Derivative liability, measurement input, term	345 days	0 days
Measurement Input, Price Volatility [Member]
Short-Term Debt [Line Items]
Derivative liability measurement input	142.94	142.94
Measurement Input, Risk Free Interest Rate [Member]
Short-Term Debt [Line Items]
Derivative liability measurement input	0.07	0

CAPITAL STOCK AND WARRANTS (Det

CAPITAL STOCK AND WARRANTS (Details Narrative)																			1 Months Ended	3 Months Ended											12 Months Ended
	Jun. 01, 2022 USD ($) $ / shares shares	Sep. 21, 2021 shares	Jul. 15, 2021 USD ($) $ / shares shares	Dec. 24, 2019 USD ($) shares	Dec. 20, 2019 USD ($) shares	Nov. 11, 2019 USD ($) shares	Oct. 18, 2019 USD ($) d	Aug. 15, 2019 USD ($) shares	May 29, 2019 shares	Apr. 16, 2019 USD ($) shares	Apr. 04, 2019 $ / shares shares	Feb. 14, 2019 USD ($) d $ / shares shares	Jan. 04, 2019 USD ($) $ / shares shares	Jul. 31, 2018 shares	Jul. 13, 2018 shares	May 25, 2017 shares	Mar. 10, 2017 shares	Feb. 03, 2017 shares	Apr. 30, 2019 USD ($)	Sep. 30, 2023 USD ($) shares	Dec. 31, 2022 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Sep. 30, 2020 USD ($) shares	Jun. 30, 2020 USD ($) shares	Mar. 31, 2020 USD ($) shares	Jun. 30, 2019 USD ($) shares	Mar. 31, 2019 USD ($) shares	Dec. 31, 2023 USD ($) $ / shares shares	Sep. 30, 2024	Mar. 11, 2021 $ / shares shares
Class of Stock [Line Items]
Stock issued new issues | shares																	26,905,969
Debt conversion, converted instrument, shares issued | shares				637,273	1,468,204	1,748,363														36,000,000					261,215,948	115,277,834	27,563,525	21,484,688
Debt instrument, face amount				$ 10,000	$ 29,000	$ 53,705
Interest payable				$ 515	$ 4,015	$ 2,680														$ 0
Number of shares issued for services | shares								175,000
Fair value of shares charged to other operating expenses																													$ 75,880
Number of shares charged to other operating expenses | shares																													542,000
Fair value of common stock								$ 12,250
Debt instrument, interest rate, percentage																																24%
Excess of fair value																									$ 462,263	$ 467,554	$ 132,838	$ 228,949
Debt conversion, converted instrument, amount																				36,000					804,324	797,067	210,532	406,093
Liability reduction																									$ 342,061	$ 329,512	$ 77,695	$ 177,143
Notes payable																				$ 36,000
Convertible Notes [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, shares issued | shares																									261,215,948	115,277,834	27,563,525	21,484,688
Debt instrument, face amount																									$ 325,212	$ 311,050	$ 67,082	$ 165,350
Interest payable																									$ 16,849	$ 18,462	$ 10,613	$ 11,793
Notes Payable [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, shares issued | shares																								13,795,118
Interest payable																								$ 814
Debt conversion, converted instrument, amount																								45,525
Notes payable																								$ 22,500
Second FirstFire Note [Member]
Class of Stock [Line Items]
Issuance of warrants																							$ 262,429
Debt conversion, original debt, amount																							$ 39,000
FirstFire Note [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, shares issued | shares	25,000,000		10,000,000																		64,000,000	135,000,000									72,000,000
Debt instrument, face amount			$ 52,080																												$ 72,000
Debt instrument, convertible, conversion price | $ / shares	$ 0.001		$ 0.005208																		$ 0.001	$ 0.001									$ 0.001
Debt conversion, converted instrument, amount	$ 25,000																				$ 64,000	$ 135,000
Two Consulting Firm Entities [Member]
Class of Stock [Line Items]
Number of shares issued for services | shares									542,000
Emet Capital Partners LLC [Member] | Two Exchange Agreement [Member]
Class of Stock [Line Items]
Debt instrument, face amount							$ 20,399
Interest payable							5,189
Debt instrument, periodic payment							$ 25,587
Debt instrument, interest rate, percentage							6%
Debt instrument, maturity date							Feb. 12, 2020
Debt instrument, interest rate, percentage							75%
Debt convertible threshold trading days | d							15
Emet Capital Partners LLC [Member] | Second Exchange Agreement [Member]
Class of Stock [Line Items]
Stock issued new issues | shares												9,000,000
Debt instrument, periodic payment												$ 675,000
Debt instrument, interest rate, percentage												2%
Debt instrument, maturity date												Oct. 18, 2020
Debt instrument, interest rate, percentage												75%
Debt convertible threshold trading days | d												15
Common Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted | shares		15,000,000
Emet Capital Partners LLC [Member]
Class of Stock [Line Items]
Stock issued new issues | shares										1,384,600	695,129																		1,384,600
Debt conversion, converted instrument, shares issued | shares													769,785																	769,785
Debt instrument, face amount										$ 40,500			$ 670
Interest payable										$ 7,961			$ 100
Debt instrument, convertible, conversion price | $ / shares													$ 0.001
Excess of common stock value																													$ 131,537	$ 99,302
Fair value of common stock																			$ 179,998											100,072
Loss on conversion of debt																													$ 47,961	$ 770
Number of warrant issued | shares											1,400					440,000
Exercise price of warrants | $ / shares											$ 0.001
FirstFire Global Opportunities Fund, LLC [Member] | Warrant A [Member]
Class of Stock [Line Items]
Exercise price of warrants | $ / shares																																	$ 0.025
Warrant purchase of common stock | shares																																	25,000,000
FirstFire Global Opportunities Fund, LLC [Member] | Warrant B [Member]
Class of Stock [Line Items]
Exercise price of warrants | $ / shares																																	$ 0.05
Warrant purchase of common stock | shares																																	15,000,000
FirstFire Global Opportunities Fund, LLC [Member] | Warrant C [Member]
Class of Stock [Line Items]
Exercise price of warrants | $ / shares																																	$ 0.075
Warrant purchase of common stock | shares																																	10,000,000
FirstFire Global Opportunities Fund, LLC [Member] | Warrant [Member]
Class of Stock [Line Items]
Exercise price of warrants | $ / shares																																	$ 0.005
Series B Convertible Preferred Stock [Member] | Emet Capital Partners LLC [Member]
Class of Stock [Line Items]
Stock issued new issues | shares												9,000,000
Preferred stock, conversion basis												Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $0.075 per share.
Preferred stock, conversion price | $ / shares												$ 0.075
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted | shares		300,000
Green C Corporation [Member] | Common Class A [Member]
Class of Stock [Line Items]
Business acquisition, percentage of voting interests acquired														100%
Green C Corporation [Member] | Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued new issues | shares														9,411,998	9,411,998
Preferred stock, conversion basis															Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock.
Sylios Corp [Member]
Class of Stock [Line Items]
Business acquisition, percentage of voting interests acquired																	19.99%	80.01%
Stock issued new issues | shares																	5,378,476	21,527,493
Common stock, shares held | shares																		500

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)					3 Months Ended			9 Months Ended		12 Months Ended
	May 27, 2020	Jul. 15, 2019	Jul. 31, 2018	Jun. 21, 2018	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2020	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2019
Loss Contingencies [Line Items]
Officers compensation					$ 30,000	$ 30,000		$ 90,000	$ 90,000
Pharmedica Ltd [Member]
Loss Contingencies [Line Items]
Royalty expense										$ 50,000
Asset impairment charges										69,749
Reduction of carrying value of assets										69,749
Intangible assets, net										$ 0
Sub License Agreement [Member] | Symtomax Unipessoal IDA [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Annual royalties rate		10%
Sub License Agreement [Member] | Symtomax Unipessoal IDA [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Annual royalties rate		17%
Payments for royalties	$ 1,000,000
Services Agreements [Member]
Loss Contingencies [Line Items]
Officers compensation								$ 90,000	$ 90,000
Services Agreements [Member] | Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Officers compensation			$ 10,000
Green C Corporation [Member] | Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Cost, direct tax and license				$ 100,000
Annual royalties rate				5%
Royalty expense				$ 50,000
Forgiveness of royalty payable							$ 50,000
Reduction of accrued royalties							50,000
Accrued royalties							$ 0